Израиль -
иврит -
Ministry of Health
ארלזי 25
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 25 mg / 0.5 ml - etanercept
Израиль -
иврит -
Ministry of Health
ארלזי 50
novartis israel ltd - etanercept - תמיסה להזרקה - etanercept 50 mg / 1 ml - etanercept
Израиль -
иврит -
Ministry of Health
אורנסיה 125 מג תת - עורי
bristol, myers squibb (israel) limited, israel - abatacept - תמיסה להזרקה - abatacept 125 mg/ml - abatacept - abatacept - orencia is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. orencia may be used as monotherapy or concomitantly with disease-modifying antirheumatic drugs (dmards) other than tumor necrosis factor (tnf) antagonists.
Израиль -
иврит -
Ministry of Health
דופיקסנט 300 מג
sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 150 mg/ml - dupilumab
Израиль -
иврит -
Ministry of Health
דופיקסנט 200 מג
sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 175 mg/ml - dupilumab
Израиль -
иврит -
Ministry of Health
סאפנלו
astrazeneca (israel) ltd - anifrolumab - תרכיז להכנת תמיסה לאינפוזיה - anifrolumab 150 mg/ml - anifrolumab
Израиль -
иврит -
Ministry of Health
סיבינקו 100 מג
pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 100 mg - abrocitinib
Израиль -
иврит -
Ministry of Health
סיבינקו 200 מג
pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 200 mg - abrocitinib
Израиль -
иврит -
Ministry of Health
סיבינקו 50 מג
pfizer pharmaceuticals israel ltd - abrocitinib - טבליות מצופות פילם - abrocitinib 50 mg - abrocitinib
Израиль -
иврит -
Ministry of Health
אנברל אבקה וממס
pfizer pharmaceuticals israel ltd - etanercept - אבקה וממס להכנת תמיסה להזרקה - etanercept 25 mg/vial - etanercept - etanercept - * rheumatoid arthritis:enbrel is indicated for the treatment of active rhematoid arthritis in adults when the response to disease-modifying antirheumatic drugs (dmards) including methotrexate (unless contraindicated) has been inadequate.. enbrel can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone. reducing signs and symptoms and inhibiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function.* polyarticular juvenile idiopathic arthritis: treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate. enbrel has not been studied in children aged less than 2 years.* psoriatic arthritistreatment of ac